SULZER
14.3.2017 14:02:23 CET | Business Wire | Press release
Sulzer’s newly developed Blueline cartridge system is designed specifically for the application of highly viscous materials, with a view to enhancing end users’ productivity. Blueline delivers a threefold increase in dispensing rates compared with conventional cartridge systems. It is compatible with commonly used dispensers and will be unveiled at the JEC World 2017 exhibition in Paris.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170314005752/en/
Sulzer Mixpac AG – a subsidiary of Sulzer Ltd., a global leader in the manufacture and supply of liquid application and mixing technology products and services – will showcase its innovative new Blueline cartridge system at JEC World 2017 in Paris.
Dispensing rates up to three times higher
Highly viscous materials push existing cartridge systems to their limits in terms of the achievable dispensing rate. Previously, users would have to make do with small quantities of such materials or switch to considerably more complex mechanical processing of adhesives. Available with 2:1 and 10:1 mixing ratios, the Blueline cartridge system opens up a host of new possibilities.
Applications in aircraft and vehicle construction, general industry and the building sector
Marco Frei, Head Sales Industry EMIRA at Sulzer Mixpac AG, explains: “Blueline extends the range of possible applications for cartridges , allowing end users to boost productivity. Compared with existing systems, it offers considerably higher dispensing rates when applying highly viscous materials. The large cross-sections of the outlets combined with new, optimised mixing geometry increases dispensing rates up to threefold compared with currently available cartridge systems – and all this with the same dispensing force. The interface design features separate outlets from the cartridge to the mixer, removing the risk of unintentional mixing and clogging of the cartridge outlet by material components. This translates into clean and reliable processing of two-component materials.”
Quick, safe and clean processing of sensitive 2-K materials
Honeycomb core and edging filler are applied in two-component (2-K) form in sectors such as aircraft construction. These materials have densities of less than 1g/ml and are formed by adding hollow plastic or glass spheres, which helps to reduce weight. When processing such materials, high pressure and high shear rates cause these spheres to burst, making them unusable. In addition, these materials are also highly viscous, and in some cases there are differences in compressibility between the two components. For these reasons, the options for processing such materials using cartridge systems were previously extremely limited. The new Blueline system changes all this – it opens up a host of totally new possibilities, allowing for the rapid, safe and clean processing of sensitive 2-K materials with the help of cartridge systems.
JEC in Paris
The JEC trade fair is the world’s largest composites exhibition, making it the ideal platform for Sulzer Mixpac to introduce its Blueline system and showcase its entire range of dispensers and cartridge-based application systems.
Blueline – key facts
- For highly viscous materials that are difficult to apply
- For high dispensing rates (threefold increase in dispensing quantity)
- For materials sensitive to pressure and shearing
- Compatible with commonly used MIXPAC dispensers
Sulzer Mixpac at JEC World 2017
Paris Nord Villepinte Exhibition Centre, hall 6, stand A62
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005752/en/
Contact:
Sulzer
Gerald Fleisch
Head of Marketing Sulzer Mixpac, Sulzer
Mixpac Ltd
Tel: +41 (0)81 772 2164
gerald.fleisch@sulzer.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
